The effect of cocoa supplementation on hepatic steatosis, reactive oxygen species and LFABP in a rat model of NASH

Comparative Hepatology

Volumn 10, Issue , 2011, Pages

  Janevski, Mile ^a   Antonas, Kiriakos N ^b   Sullivan Gunn, Melanie J ^a   McGlynn, Maree A ^b   Lewandowski, Paul A ^a  

^a DEAKIN UNIVERSITY   (Australia)

^b VICTORIA UNIVERSITY   (Australia)

Author keywords

Antioxidant; Cocoa; Liver fatty acid binding protein; Nadph oxidase; Nash, oxidative stress; Non alcoholic steatohepatitis

Indexed keywords

CHOLINE; FATTY ACID BINDING PROTEIN; GLUTATHIONE; MESSENGER RNA; METHIONINE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CACAO; CONTROLLED STUDY; DIET SUPPLEMENTATION; DISEASE SEVERITY; ERYTHROCYTE LEVEL; FEMALE; HEPATITIS; HISTOPATHOLOGY; LIPID DIET; LIVER FIBROSIS; LIVER LEVEL; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; RAT;

EID: 81055138797     PISSN: None     EISSN: 14765926     Source Type: Journal    
DOI: 10.1186/1476-5926-10-10     Document Type: Article

References (29)

1. Petta S, Muratore C, Craxi A. Non-alcoholic fatty liver disease pathogenesis: the present and the future. Dig Liver Dis 2009, 41:615-625. 10.1016/j.dld.2009.01.004, 19223251.
2. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005, 115:209-218. 546435, 15690074.
3. Pusl T, Wild N, Vennegeerts T, Wimmer R, Goke B, Brand S, Rust C. Free fatty acids sensitize hepatocytes to bile acid-induced apoptosis. Biochem Biophys Res Commun 2008, 371:441-445. 10.1016/j.bbrc.2008.04.113, 18452708.
4. Chitturi S, Farrell GC, Hashimoto E, Saibara T, Lau GK, Sollano JD. Non-alcoholic fatty liver disease in the Asia-Pacific region: definitions and overview of proposed guidelines. J Gastroenterol Hepatol 2007, 22:778-787. 10.1111/j.1440-1746.2007.05001.x, 17565630.
5. Rector RS, Thyfault JP, Wei Y, Ibdah JA. Non-alcoholic fatty liver disease and the metabolic syndrome: an update. World J Gastroenterol 2008, 14:185-192. 10.3748/wjg.14.185, 2675112, 18186553.
6. Day CP, Saksena S. Non-alcoholic steatohepatitis: definitions and pathogenesis. J Gastroenterol Hepatol 2002, 17(Suppl 3):S377-384.
7. George J, Pera N, Phung N, Leclercq I, Yun Hou J, Farrell G. Lipid peroxidation, stellate cell activation and hepatic fibrogenesis in a rat model of chronic steatohepatitis. J Hepatol 2003, 39:756-764. 10.1016/S0168-8278(03)00376-3, 14568258.
8. Martin GG, Atshaves BP, McIntosh AL, Payne HR, Mackie JT, Kier AB, Schroeder F. Liver fatty acid binding protein gene ablation enhances age-dependent weight gain in male mice. Mol Cell Biochem 2009, 324:101-115. 10.1007/s11010-008-9989-9, 2835309, 19104910.
9. Yan J, Gong Y, She YM, Wang G, Roberts MS, Burczynski FJ. Molecular mechanism of recombinant liver fatty acid binding protein's antioxidant activity. J Lipid Res 2009, 50:2445-2454. 10.1194/jlr.M900177-JLR200, 2781316, 19474456.
10. Kono H, Rusyn I, Yin M, Gabele E, Yamashina S, Dikalova A, Kadiiska MB, Connor HD, Mason RP, Segal BH, et al. NADPH oxidase-derived free radicals are key oxidants in alcohol-induced liver disease. J Clin Invest 2000, 106:867-872. 10.1172/JCI9020, 517812, 11018074.
11. dela Pena A, Leclercq IA, Williams J, Farrell GC. NADPH oxidase is not an essential mediator of oxidative stress or liver injury in murine MCD diet-induced steatohepatitis. J Hepatol 2007, 46:304-313. 10.1016/j.jhep.2006.08.025, 17157947.
12. de Alwis NM, Day CP. Non-alcoholic fatty liver disease: the mist gradually clears. J Hepatol 2008, 48(Suppl 1):S104-112.
13. Lotito SB, Actis-Goretta L, Renart ML, Caligiuri M, Rein D, Schmitz HH, Steinberg FM, Keen CL, Fraga CG. Influence of oligomer chain length on the antioxidant activity of procyanidins. Biochem Biophys Res Commun 2000, 276:945-951. 10.1006/bbrc.2000.3571, 11027573.
14. Matsui N, Ito R, Nishimura E, Yoshikawa M, Kato M, Kamei M, Shibata H, Matsumoto I, Abe K, Hashizume S. Ingested cocoa can prevent high-fat diet-induced obesity by regulating the expression of genes for fatty acid metabolism. Nutrition 2005, 21:594-601. 10.1016/j.nut.2004.10.008, 15850966.
15. Grassi D, Necozione S, Lippi C, Croce G, Valeri L, Pasqualetti P, Desideri G, Blumberg JB, Ferri C. Cocoa reduces blood pressure and insulin resistance and improves endothelium-dependent vasodilation in hypertensives. Hypertension 2005, 46:398-405. 10.1161/01.HYP.0000174990.46027.70, 16027246.
16. McKim SE, Konno A, Gabele E, Uesugi T, Froh M, Sies H, Thurman RG, Arteel GE. Cocoa extract protects against early alcohol-induced liver injury in the rat. Arch Biochem Biophys 2002, 406:40-46. 10.1016/S0003-9861(02)00425-3, 12234488.
17. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005, 41:1313-1321. 10.1002/hep.20701, 15915461.
18. Pastore A, Federici G, Bertini E, Piemonte F. Analysis of glutathione: implication in redox and detoxification. Clinica chimica acta 2003, 333:19-39.
19. Serrander L, Cartier L, Bedard K, Banfi B, Lardy B, Plastre O, Sienkiewicz A, Forro L, Schlegel W, Krause KH. NOX4 activity is determined by mRNA levels and reveals a unique pattern of ROS generation. Biochem J 2007, 406:105-114. 10.1042/BJ20061903, 1948990, 17501721.
20. Schmittgen TD, Zakrajsek BA, Mills AG, Gorn V, Singer MJ, Reed MW. Quantitative reverse transcription-polymerase chain reaction to study mRNA decay: comparison of endpoint and real-time methods. Anal Biochem 2000, 285:194-204. 10.1006/abio.2000.4753, 11017702.
21. Nan YM, Wu WJ, Fu N, Liang BL, Wang RQ, Li LX, Zhao SX, Zhao JM, Yu J. Antioxidants vitamin E and 1-aminobenzotriazole prevent experimental non-alcoholic steatohepatitis in mice. Scand J Gastroenterol 2009, 44:1121-1131. 10.1080/00365520903114912, 19606393.
22. Martin GG, Atshaves BP, Huang H, McIntosh AL, Williams BJ, Pai PJ, Russell DH, Kier AB, Schroeder F. Hepatic phenotype of liver fatty acid binding protein gene-ablated mice. Am J Physiol Gastrointest Liver Physiol 2009, 297:G1053-1065. 10.1152/ajpgi.00116.2009, 2850096, 19815623.
23. Rajaraman G, Wang GQ, Yan J, Jiang P, Gong Y, Burczynski FJ. Role of cytosolic liver fatty acid binding protein in hepatocellular oxidative stress: effect of dexamethasone and clofibrate treatment. Mol Cell Biochem 2007, 295:27-34. 10.1007/s11010-006-9268-6, 16924418.
24. Musso G, Gambino R, Cassader M. Non-alcoholic fatty liver disease from pathogenesis to management: an update. Obes Rev 2010, 11:430-445.
25. Skrtic S, Carlsson L, Ljungberg A, Linden D, Michalik L, Wahli W, Oscarsson J. Decreased expression of peroxisome proliferator-activated receptor alpha and liver fatty acid binding protein after partial hepatectomy of rats and mice. Liver Int 2005, 25:33-40. 10.1111/j.1478-3231.2004.0998.x, 15698396.
26. Lewandowski P, Cameron-Smith D, Moulton K, Walder K, Sanigorski A, Collier GR. Disproportionate increase of fatty acid binding proteins in the livers of obese diabetic Psammomys obesus. Ann N Y Acad Sci 1997, 827:536-540. 10.1111/j.1749-6632.1997.tb51866.x, 9329786.
27. Bioulac-Sage P, Laumonier H, Laurent C, Zucman-Rossi J, Balabaud C. Hepatocellular adenoma: what is new in 2008. Hepatol Int 2008, 2:316-321. 10.1007/s12072-008-9075-0, 2716879, 19669260.
28. Kono H, Rusyn I, Uesugi T, Yamashina S, Connor HD, Dikalova A, Mason RP, Thurman RG. Diphenyleneiodonium sulfate, an NADPH oxidase inhibitor, prevents early alcohol-induced liver injury in the rat. Am J Physiol Gastrointest Liver Physiol 2001, 280:G1005-1012.
29. Yamaguchi K, Yang L, McCall S, Huang J, Yu XX, Pandey SK, Bhanot S, Monia BP, Li YX, Diehl AM. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology 2007, 45:1366-1374. 10.1002/hep.21655, 17476695.